Cardiovascular mortality has remained high in patients on peritoneal dialysis (PD) due to the high prevalence of various cardiovascular complications including coronary artery disease, left ventricular hypertrophy and dysfunction, heart failure, arrhythmia (especially atrial fibrillation), cerebrovascular disease, and peripheral arterial disease. In addition, nearly a quarter of PD patients develop sudden cardiac death as the terminal life event. Thus, it is essential to identify effective treatment that may lower cardiovascular mortality and improve survival of PD patients. The International Society for Peritoneal Dialysis (ISPD) commissioned a global workgroup in 2012 to formulate a series of recommendation statements regarding lifestyle modification, assessment and management of various cardiovascular risk factors, and management of the various cardiovascular complications to be published in 2 guideline documents. This publication forms the second part of the guideline documents and includes recommendation statements on the management of various cardiovascular complications in adult chronic PD patients. The documents are intended to serve as a global clinical practice guideline for clinicians who look after PD patients. We also define areas where evidence is clearly deficient and make suggestions for future research in each specific area.
HerzogC.A., MaJ.Z., CollinsA.J.Poor long-term survival after acute myocardial infarction among patients on long-term dialysis.N Engl J Med1998; 339: 799–805.
2.
StackA.G., SaranR.Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States.Am J Kidney Dis2002; 40: 1202–10.
3.
WangA.Y., WangM., WooJ., LamC.W., LuiS.F., LiP.K.Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients.J Am Soc Nephrol2004; 15: 2186–94.
4.
WangA.Y., WangM., LamC.W., ChanI.H., LuiS.F., SandersonJ.E.Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis.Clin J Am Soc Nephrol2011; 6: 805–12.
5.
WangA.Y., WangM., LamC.W., ChanI.H., LuiS.F., SandersonJ.E.Heart failure with preserved or reduced ejection fraction in patients treated with peritoneal dialysis.Am J Kidney Dis2013; 61: 975–83.
6.
TrespalaciosF.C., TaylorA.J., AgodoaL.Y., BakrisG.L., AbbottK.C.Heart failure as a cause for hospitalization in chronic dialysis patients.Am J Kidney Dis2003; 41: 1267–77.
7.
CollinsA.J., FoleyR.N., ChaversB., GilbertsonD., HerzogC., JohansenK.United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States.Am J Kidney Dis2012; 59(1 Suppl 1): A7, e1–420.
8.
WangA.Y., LamC.W., ChanI.H., WangM., LuiS.F., SandersonJ.E.Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis.Hypertension2010; 56: 210–6.
9.
WangH.H., HungS.Y., SungJ.M., HungK.Y., WangJ.D.Risk of stroke in long-term dialysis patients compared with the general population.Am J Kidney Dis2014; 63: 604–11.
WizemannV., TongL., SatayathumS., DisneyA., AkibaT., FissellR.B.Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy.Kidney Int2010; 77: 1098–106.
12.
GenovesiS., VincentiA., RossiE., PoglianiD., AcquistapaceI., StellaA.Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.Am J Kidney Dis2008; 51: 255–62.
13.
WangA.Y., Wai-Kei LamC.The diagnostic utility of cardiac biomarkers in dialysis patients.Semin Dial2012; 25: 388–96.
14.
MelloniC., AlexanderK P., Milford-BelandS., NewbyL.K., SzczechL.A. Crusade Investigators, et al. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease.Clin Cardiol2008; 31: 125–9.
15.
NewbyL.K., JesseR.L., BabbJ.D., ChristensonR.H., De FerT.M., DiamondG.A.ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents.J Am Coll Cardiol2012; 60: 2427–63.
16.
NACB Writing Group, Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, et al.National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure.Clin Chem2007; 53: 2086–96.
17.
GargR., SinghA., KhajaA., MartinA., AggarwalK.How does volume status affect BNP and troponin levels as markers of cardiovascular status in peritoneal dialysis?Congest Heart Fail2009; 15: 240–4.
18.
GowdakL.H., ArantesR.L., de PaulaF.J., KriegerE.M., De LimaJ.J.Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients.Ren Fail2007; 29(5): 559–65.
19.
LentineK.L., CostaS.P., WeirM.R., RobbJ.F., FleisherL.A. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Diseas, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology.J Am Coll Cardiol2012; 60: 434–80.
20.
FriedmanS.E., PalacR.T., ZlotnickD.M., ChobanianM.C., CostaS.P.A call to action: variability in guidelines for cardiac evaluation before renal transplantation.Clin J Am Soc Nephrol2011; 6: 1185–91.
21.
SharmaR., PellerinD., GazeD.C., GregsonH., StreatherC.P., CollinsonP.O.Dobutamine stress echocardiography and the resting but not exercise electrocardiograph predict severe coronary artery disease in renal transplant candidates.Nephrol Dial Transplant2005; 20: 2207–14.
22.
RabbatC.G., TreleavenD.J., RussellJ.D., LudwinD., CookD.J.Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis.J Am Soc Nephrol2003; 14: 431–9.
23.
Tomaszuk-KazberukA., KozuchM., MalyszkoJ., Bachorzewska-GajewskaH., DobrzyckiS., MusialW.J.Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: do we follow the guidelines?Ren Fail2013; 35(2): 235–42.
24.
DempsterD.W., RosenstockJ.L., SchwimmerJ.A., PanagopoulosG., DeVitaM.V., MichelisM.F.Underutilization of aspirin in hemodialysis patients for primary and secondary prevention of cardiovascular disease.Clin Nephrol2005; 64(5): 371–7.
25.
PalmerS.C., Di MiccoL., RazavianM., CraigJ.C., PerkovicV., PellegriniF.Antiplatelet agents for chronic kidney disease.Cochrane Database Syst Rev2013; 2: CD008834.
26.
WangA.Y., WangM., LamC.W., ChanI.H., ZhangY., SandersonJ.E.Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease.Hypertension2008; 52: 107–14.
27.
ZannadF., KesslerM., LehertP., GrünfeldJ.P., ThuilliezC., LeizoroviczA.Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies.Kidney Int2006; 70: 1318–24.
28.
TakahashiA., TakaseH., ToriyamaT., SugiuraT., KuritaY., UedaR.Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis—a randomized study.Nephrol Dial Transplant2006; 21: 2507–12.
29.
CiceG., Di BenedettoA., D'IsaS., D'AndreaA., MarcelliD., GattiE.Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.J Am Coll Cardiol2010; 56: 1701–8.
30.
YangL.Y., GeX., WangY.L., MaK.L., LiuH., ZhangX.L.Angiotensin receptor blockers reduce left ventricular hypertrophy in dialysis patients: a meta-analysis.Am J Med Sci2013; 345: 1–9.
31.
CiceG., FerraraL., Di BenedettoA., RussoP.E., MarinelliG., PaveseF.Dilated cardiomyopathy in dialysis patients—beneficial effects of carvedilol: a double-blind, placebo-controlled trial.J Am Coll Cardiol2001; 37: 407–11.
32.
CiceG., FerraraL., D'AndreaA., D'IsaS., Di BenedettoA., CittadiniA.Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial.J Am Coll Cardiol2003; 41: 1438–44.
33.
ItoY., MizunoM., SuzukiY., TamaiH., HiramatsuT. Nagoya Spiro Study Group, et al., Long-term effects of spironolactone in peritoneal dialysis patients.J Am Soc Nephrol2014; 25: 1094–102.
34.
MatsumotoY., MoriY., KageyamaS., AriharaK., SugiyamaT., OhmuraH.Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients.J Am Coll Cardiol2014; 63: 528–36.
35.
FurieK.L., KasnerS.E., AdamsR.J., AlbersG.W., BushR.L., FaganS.C.Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke2011; 42: 227–76.
36.
GoldsteinL.B., BushnellC.D., AdamsR.J., AppelL.J., BraunL.T., ChaturvediS.Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke2011; 42: 517–84.
37.
PalmerS.C., di MiccoL., RazavianM., CraigJ.C., PerkovicV., PellegriniF.Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis.Ann Intern Med2012; 156: 445–59.
38.
FurieK.L., GoldsteinL.B., AlbersG.W., KhatriP., NeyensR., TurakhiaM.P.Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association.Stroke2012; 43: 3442–53.
39.
ElliottM.J., ZimmermanD., HoldenR.M.Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates.Am J Kidney Dis2007; 50(3): 433–40.
40.
ZimmermanD., SoodM.M., RigattoC., HoldenR.M., HiremathS., ClaseC.M.Systematic review and meta-analysis of incidence, prevalence and outcome of atrial fibrillation in patients on dialysis.Nephrol Dial Transplant2012; 27: 3816–22.
41.
HeidbuchelH., VerhammeP., AlingsM., AntzM., HackeW., OldgrenJ.EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.Eur Heart J2013; 34(27): 2094–106.
42.
CoveC.L., HylekE.M.An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.J Am Heart Assoc2013; 2(5): e000136.
43.
TariqN., AdilM.M., SaeedF., ChaudhryS.A., QureshiA.I.Outcomes of thrombolytic treatment for acute ischemic stroke in dialysis-dependent patients in the United States.J Stroke Cerebrovasc Dis2013; 22(8): e354–59.
44.
KDIGO2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD.Kidney Int2013; 83: 91–111.
45.
HirschA.T., HaskalZ.J., HertzerN.R., BakalC.W., CreagerM.A., HalperinJ.L.ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.Circulation2006; 113: e463–654.
46.
HirschA.T., HaskalZ.J., HertzerN.R., BakalC.W., CreagerM.A., HalperinJ.L.ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary. A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.J Am Coll Cardiol2006; 47: 1239–312.
47.
NorgrenL., HiattW.R., DormandyJ.A., NehlerM.R., HarrisK.A., FowkesF.G.Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).Eur J Vasc Endovasc Surg2007; 33(Suppl 1): S1–75.
48.
FransF.A., BipatS., ReekersJ.A., LegemateD.A., KoelemayM.J.Systematic review of exercise training or percutaneous transluminal angioplasty for intermittent claudication.Br J Surg2012; 99: 16–28.
49.
WatsonL., EllisB., LengG.C.Exercise for intermittent claudication.Cochrane Database Syst Rev2008; CD000990.
50.
K/DOQI Workgroup et al. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.Am J Kidney Dis2005; 45: S1–153.
51.
HerzogC.A., AsingerR.W., BergerA.K., CharytanD.M., DiezJ., HartR.G.Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).Kidney Int2011; 80: 572–86.
52.
AbbottK.C., TrespalaciosF.C., TaylorA.J., AgodoaL.Y.Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality.BMC Nephrol2003; 4: 1–10.
53.
GenovesiS., PoglianiD., FainiA., ValsecchiM.G., RivaA., StefaniF.Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients.Am J Kidney Dis2005; 46: 897–902.
54.
VazquezE., Sanchez-PeralesC., LozanoC., Garcia-CortesM.J., BorregoF., GuzmanM.Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis.Am J Cardiol2003; 92: 868–71.
PunP.H., LehrichR.W., SmithS.R., MiddletonJ.P.Predictors of survival after cardiac arrest in outpatient hemodialysis clinics.Clin J Am Soc Nephrol2007; 2: 491–500.
57.
TangriN., ShastriS., TighiouartH., BeckG.J., CheungA.K., EknoyanG.B-blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO study.Am J Kidney Dis2011; 58(6): 939–45.
58.
GreenbergH., CaseR.B., MossA.J., BrownM.W., CarrollE.R., AndrewsM.L.; MADIT-II Investigators Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II).J Am Coll Cardiol2004; 43(8): 1459–65.
59.
HerzogC.A., LiS., WeinhandlE.D., StriefJ.W., CollinsA.J., GilbertsonD.T.Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators.Kidney Int2005; 68(2): 818–85.
